| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Apr―23 |
Allergy-like nocebo events reported with COVID-19 vaccines: a case control study |
Virginie Bres, Najah Ben Fadhel, Raphael Trouillet, Guillaume Broc, Anca Chiriac, Jean-Luc Faillie |
| 2 |
[GO] |
2025―Feb―10 |
The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system |
Hui Qiu, Li He, Jianzhu Zhou, Zeying Feng, Ling Ye, Tong Li, et al. (+5) Xin Huang, Longjian Huang, Chengjun Guo, Shaojun Chen, Chengxian Guo |
| 3 |
[GO] |
2024―Dec―30 |
Influence of rapidly increased numbers of reports on adverse events of the COVID-19 vaccine in the Japanese pharmacovigilance database on disproportionality analysis of antineoplastic drug-associated adverse cardiovascular events |
Hajime Matsuo, Hiroyuki Tanaka, Kiri Endo, Toshihiro Ishii |
| 4 |
[GO] |
2024―Jun―19 |
Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic |
Jean-Luc Cracowski, Mathieu Molimard, Vincent Richard, Matthieu Roustit, Charles Khouri |
| 5 |
[GO] |
2024―Apr―26 |
Analysis of new-onset seizures following use of COVID-19 vaccinations in children based on VAERS |
Yanhui Liu, Jinyang He, Xiaozhu Zhou, Yi Wu, Heping Cai, Yuquan Sun, Xiangli Cui |
| 6 |
[GO] |
2024―Feb―12 |
Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program |
Daniel A. Salmon, Robert T. Chen, Steve Black, Joshua Sharfstein |
| 7 |
[GO] |
2023―Oct―05 |
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands |
C. Ouaddouh, J.W. Duijster, T. Lieber, F.P.A.M. van Hunsel |
| 8 |
[GO] |
2023―Jul―21 |
Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS |
Fuhong Qin, Huiling Wang, Meng Li, Shengnan Zhuo, Wei Liu |
| 9 |
[GO] |
2023―Jul―07 |
Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher Clostridioides difficile infection rate |
Marko Lucijanic, Nikolina Busic, Josip Stojic, Mislav Barisic-Jaman, Nikola Zagorec, Karla Lazibat, et al. (+6) Antica Pasaric, Anamarija Vrkljan Vuk, Ivan Durlen, Josko Mitrovic, Ivica Luksic, Bruno Barsic |
| 10 |
[GO] |
2023―Feb―17 |
Medication errors during a pandemic: what have we learnt? |
Ahmad Z. Al Meslamani |
| 11 |
[GO] |
2023―Jan―24 |
Can COVID-19 have a Clinically Significant Effect on Drug Metabolism? |
Felicia Ceban, Mehala Subramaniapillai, Rodrigo B. Mansur, Joshua D. Rosenblat, Roger S. McIntyre |
| 12 |
[GO] |
2023―Jan―04 |
Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review |
Giacomo Casalini, Andrea Giacomelli, Spinello Antinori |
| 13 |
[GO] |
2022―Nov―14 |
A cross-sectional study on substandard and falsified medicines (fake or counterfeit drugs) in UK pharmacies during the COVID-19 pandemic |
Ravina Barrett |
| 14 |
[GO] |
2022―Sep―30 |
Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database |
Yunfei Zhao, Huiling Wang, Qingsong Zhang, Yongxin Hu, Yulong Xu, Wei Liu |
| 15 |
[GO] |
2022―Sep―09 |
Safety and efficacy of monoclonal antibodies anti SARS-CoV-2 in pregnancy |
Antonio Riccardo Buonomo, Nunzia Esposito, Isabella Di Filippo, Gabriele Saccone, Biagio Pinchera, Riccardo Scotto, et al. (+2) Giuseppe Bifulco, Ivan Gentile |
| 16 |
[GO] |
2022―Aug―31 |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom |
Matilde Otero-Losada, Nikolai Petrovsky, Abdallah Alami, James A.G. Crispo, Donald Mattison, Francisco Capani, et al. (+3) Christopher Goetz, Daniel Krewski, Santiago Perez-Lloret |
| 17 |
[GO] |
2022―Aug―02 |
Pharmacovigilance regulatory actions by national pharmacovigilance centres in Arab countries following COVID-19 pandemic |
Sameh A. Al-Zubiedi, Manal Younus, Sara AL-Khalidi, Magnus Ekilo, Thamir M. Alshammari |
| 18 |
[GO] |
2022―May―16 |
Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions |
María Sainz-Gil, Nieves Merino Kolly, Verónica Velasco-González, Zoraida Verde Rello, Ana M Fernandez-Araque, Rosario Sanz Fadrique, Luis H Martín Arias |
| 19 |
[GO] |
2021―Aug―23 |
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism |
Yajnavalka Banerjee, Anca Pantea Stoian, José Silva-Nunes, Alper Sonmez, Ali A. Rizvi, Andrej Janez, Manfredi Rizzo |
| 20 |
[GO] |
2021―Jul―30 |
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data |
Anika Singh, Ashwin Kamath |
| 21 |
[GO] |
2021―Jul―15 |
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines |
Maurizio Sessa, Kristian Kragholm, Anders Hviid, Morten Andersen |
| 22 |
[GO] |
2021―Jun―24 |
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database |
Jaykaran Charan, Siddhartha Dutta, Rimplejeet Kaur, Pankaj Bhardwaj, Praveen Sharma, Sneha Ambwani, et al. (+7) Iffat Jahan, Abdullahi Rabiu Abubakar, Salequl Islam, Timothy Craig Hardcastle, Nor Azlina A Rahman, Halyna Lugova, Mainul Haque |
| 23 |
[GO] |
2020―Sep―24 |
Impact of the COVID-19 pandemic on clinical trials with drugs |
Joerg Hasford |
| 24 |
[GO] |
2020―Aug―25 |
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? |
Emanuel Raschi, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti |
| 25 |
[GO] |
2020―May―22 |
SARS-CoV-2, from its current highly contagious spreading towards the global development of an effective and safe vaccine: challenges and uncertainties |
Domenico Merante |
